Maximum human lifespan

Maximum human lifespan is the greatest age a human being has attained or, in its theoretical sense, the greatest age a human could attain under the best achievable conditions. It is a property of the extreme tail of the mortality distribution and behaves very differently from life expectancy, which is a mean. Whether the species has a fixed ceiling, and if so where, has been argued in the demographic literature since the 1990s without resolution.

§Lifespan and life expectancy

The two quantities are routinely confused. Life expectancy at birth is the mean age at death of a hypothetical cohort experiencing current age-specific mortality rates. It has risen dramatically over two centuries, mostly because fewer people die young. Maximum lifespan is a record, an order statistic drawn from the extreme right tail, and it responds far less to public-health improvement. Saving infants does not lengthen the tail; it only sends more people into it.

The distinction disciplines several common arguments. Classical claims that Bronze Age humans lived to 30 describe an average dragged down by infant mortality, not a species whose members died at 30. It also explains why record ages have crept upward far more slowly than mean ages: the tail grows because the population at risk grows, not because the biology has changed. A third quantity, Healthspan, tracks the years lived in good function and moves independently of both. Whether added years are healthy ones is the subject of Compression of morbidity.

Terminology

"Maximum lifespan" is used in at least three senses: the oldest verified individual, the age by which some specified fraction of a cohort has died, and a hypothesized biological ceiling. Papers often switch between them without warning, which accounts for a good deal of the apparent disagreement.

§The record

Jeanne Calment of Arles, France, was born on 21 February 1875 and died on 4 August 1997 at 122 years and 164 days.¹ Jean-Marie Robine and Michel Allard validated the age when she entered her 121st year, working mainly from civil and church records and censuses, supplemented by notarial documents and newspaper articles.² In the decades since, no verified case has come within three years of it. Kane Tanaka, who died in Japan in 2022 at 119 years and 107 days, and Sarah Knauss, who died in the United States in 1999 at 119 years and 97 days, rank second and third on LongeviQuest's list of validated ages. Two later holders of the title of oldest living person, Lucile Randon of France (118 years, 340 days) and Maria Branyas Morera of Spain (117 years, 168 days), died in 2023 and 2024.¹

As of November 2026 the oldest living person with a validated age is Ethel Caterham, born in Hampshire, England, on 21 August 1909, who turned 117 in a care home in Surrey on 21 August 2026.³ Guinness World Records lists her as the oldest person living,⁴ and at the end of October 2026 LongeviQuest placed her eleventh among the oldest validated people ever.¹

The stability of Calment's record is itself a data point. Over a period in which the number of people surviving past 100 rose worldwide by more than an order of magnitude, the maximum reported age at death did not rise with it. Interpretations differ sharply. One camp reads this as a ceiling; the other reads it as the ordinary behavior of a sparse extreme tail.

Calment's case has been challenged. In a 2019 paper in Rejuvenation Research, Nikolay Zak of the Moscow Society of Naturalists, crediting conversations with the geriatrician Valery Novoselov, argued that Jeanne Calment died in 1934 and that her daughter Yvonne assumed her identity.⁵ Because Yvonne was born in 1898, that would put the true age at death at about 99. A 2020 Bayesian analysis by Zak and Peter Gibbs said a definitive conclusion was not possible on the available evidence, called the validation "unsafe", and proposed DNA tests that could settle the question.⁶ A rebuttal by Robine and colleagues set out further documentation, argued that the conspiracy claims rested on inaccurate facts, and presented models in which a 122-year-old is extremely rare but plausible.⁷ LongeviQuest's validated list still ranks Calment first.¹

§The limit debate

1. 1992
   Mortality deceleration in insects
   Carey and colleagues report that death rates in medfly cohorts totalling about 1.2 million flies level off and decline at the oldest ages, contradicting a simple exponential model of aging.
2. 2016
   A claimed natural limit
   Dong, Milholland and Vijg argue in Nature that the maximum reported age at death plateaued around 1995 at about 115 years.
3. 2017
   Five rebuttals
   Nature publishes five comments disputing the 1995 breakpoint, the statistical methods and the data used.
4. 2018
   The Italian plateau
   Barbi and colleagues report in Science that the mortality hazard of Italians aged 105 and older is essentially constant, implying no hard wall at 115.
5. 2018
   Errors as an explanation
   Saul Newman argues that late-life mortality plateaus can be generated entirely by age-reporting and cohort-blending errors.
6. 2019
   A finite Dutch endpoint
   An extreme-value analysis of about 285,000 Dutch deaths at 92 or older reports an upper limit for each sex, with no upward trend over 1986-2015.
7. 2021
   No cap below 130
   Belzile and colleagues find a constant force of mortality beyond 108 in Italian and French data and call an upper bound below 130 implausible.
8. 2021
   A resilience extrapolation
   Pyrkov and colleagues extrapolate a loss of physiological resilience in blood-count and step-count data to a critical point at 120-150 years.
9. 2022
   A statistical review
   A review of the extreme-value literature concludes that any upper limit lies well beyond the highest lifetime reliably recorded.
10. 2024
    Slowing life-expectancy gains
    Olshansky and colleagues report that life-expectancy gains in the longest-lived populations have decelerated since 1990.

The idea that mortality might stop accelerating at the oldest ages predates the human data. In 1992 Carey and colleagues reported that death rates leveled off and then fell at older ages in about 1.2 million caged medflies, and argued that this cast doubt on the idea that species have absolute life-span limits.⁸ The 2016 paper by Dong, Milholland and Vijg is the reference point for the "hard limit" position in humans.⁹ Using 534 supercentenarian deaths from France, Japan, the United Kingdom and the United States in the International Database on Longevity, they reported that the yearly maximum reported age at death rose until about 1995 and then stopped, plateauing at 114.9 years (95% confidence interval 113.1-116.7). Modelling that maximum as a Poisson variable, they put the probability of anyone exceeding 125 in a given year at less than 1 in 10,000.⁹ Nature published five rebuttals in June 2017.¹⁰ Siegfried Hekimi, co-author of one, said there was no justification for splitting the data at 1995; James Vaupel told Retraction Watch that the authors had used weak statistical methods on inappropriate data; and Saul Newman, in a separate critique published in F1000Research, argued that the later decline reflected populations dropping out of the data, not a trend.¹⁰¹¹¹² Another group argued that maximum lifespan may rise to 125 years.¹³ The original authors defended their partition of the data as "data-driven".¹⁰

Barbi and colleagues took a different route. They estimated hazard rates for all 3,836 Italians aged 105 and older between 2009 and 2015 and found that the annual risk of death flattens after 105 instead of continuing to climb.¹⁴ For the 1904 birth cohort the estimated plateau corresponds to an annual probability of dying of 0.475 and a further life expectancy of 1.55 years. A flat hazard implies a long, thin tail, not a wall: if the annual risk of death holds near one in two, ages beyond 120 remain possible but exceedingly rare. Whether the plateau is real remains open. Saul Newman has argued that clerical error in age records produces plateaus of exactly this shape, and that age-estimation and cohort-blending errors at rates below 1 in 10,000 are enough to create them, an argument closely related to his later work on Blue Zones.¹⁵

Extreme-value statisticians have reached opposite verdicts from different data. An analysis of about 285,000 Dutch residents who died at 92 or older between 1986 and 2015 reported "compelling statistical evidence" of an upper limit for each sex, with no sign that the limits rose over those 30 years.¹⁶ Belzile and colleagues, analysing Italian and French semi-supercentenarians, found that a constant force of mortality beyond 108 describes the data well and that an upper bound below 130 years is implausible.¹⁷ Their 2022 review put the lower 95% confidence limits for the human lifespan at about 130 years, with point estimates that typically show no upper limit.¹⁸ Using a related exponential model with population projections, Pearce and Raftery estimated a greater than 99% probability that Calment's record will be broken by 2100, and probabilities of 89%, 44% and 13% that someone this century reaches 126, 128 or 130.¹⁹

A physiological estimate arrived from outside demography. Pyrkov and colleagues tracked fluctuations in a mortality score built from complete blood counts in a consumer laboratory database, and in step counts from wearable devices, and found that recovery from perturbations slowed steadily with age. Extrapolating that trend, they placed the complete loss of resilience at a critical point of 120-150 years and described it as an absolute limit of human lifespan.²⁰ The figure is an extrapolation well beyond the ages in the data, and five of the six authors were employees of Gero, the company that funded the study.²⁰

A separate line of work concerns averages rather than records. Olshansky and colleagues, using national data for 1990-2019 from the eight countries with the longest-lived populations plus Hong Kong and the United States, found that improvements in life expectancy have decelerated since 1990. They estimated that survival to 100 is unlikely to exceed 15% for females and 5% for males this century and concluded that, unless biological aging can be markedly slowed, radical life extension is implausible in the twenty-first century.²¹

What each side is actually claiming

The "limit" position holds that biology truncates the tail: something goes wrong at an age no current intervention touches. The "no limit" position holds only that the data cannot distinguish a truncated tail from a very thin one, not that people will live to 150. Almost nobody argues that current medicine can produce a 130-year-old.

§Verification as the binding constraint

Record quality limits every claim in this area. Validating an age of 110 requires a birth record created before the person could have had any reason to falsify it, an unbroken chain of identity documents, and an official death record. Only a small minority of claims to a very high age survive that process, and the validated lists maintained by longevity researchers are correspondingly short.

The failure modes are systematic, not random. Age exaggeration rises where pensions are linked to age, where birth registration was late or incomplete, and where a false record brings the largest reward. Japan's 2010 audit of its centenarian registry found very large numbers of people recorded as living who were dead or untraceable. Because the errors run in one direction, with records overstating age far more often than understating it, they contaminate exactly the tail that limit studies analyse.

§Biology of the extreme tail

Comparative work offers little support for a species-specific hard stop. In some organisms mortality rates do not rise measurably with age at all, the subject of Negligible senescence, and lifespan across mammals varies by more than two orders of magnitude with no obvious mechanism setting an individual ceiling. Invertebrate genetics makes the point from the other side. A daf-2 mutation roughly doubles lifespan in Caenorhabditis elegans, the result reported by Cynthia Kenyon's laboratory,²² so a species-typical maximum is not necessarily fixed, though the mammalian versions of the same manipulation move lifespan far less. Within humans, the identified genetic contributions to extreme longevity are modest and inconsistently replicated. An analysis of pedigrees covering hundreds of millions of people found that the heritability of lifespan falls well below 10% once assortative mating is accounted for.²³

Mechanistic candidates for a ceiling have been proposed, and none has held up cleanly. Telomere attrition sets a replicative limit in cultured cells but correlates weakly with human survival. Accumulated senescent cells and stem cell exhaustion progress steadily instead of hitting a threshold. Chronic sterile inflammation rises with age but is at least partly downstream of other damage. Each explains decline; none explains a wall.

Supercentenarian biology does show a compression of terminal decline. The oldest old tend to die of general frailty, systemic amyloidosis and organ failure, not of the cancers and cardiovascular events that kill people in their seventies. This is sometimes read as evidence that at the tail the aging processes themselves, and not any specific disease, become the proximate cause of death, the core premise of the Geroscience hypothesis.

§Forecasts of radical life extension

Forecasts of lifespans in the hundreds of years rest on assumed future medicine, not on extrapolation of the records above. The best-known come from Aubrey de Grey. In a 2004 essay he wrote that if mortality rates at all ages fell by 10% a year and that decline were sustained indefinitely, the first 1,000-year-old would probably be only 5-10 years younger than the first 150-year-old, the reasoning behind Longevity escape velocity.²⁴ The arithmetic of such estimates is discussed under negligible senescence.

Mainstream biogerontologists have rejected the timescale. In 2005, 28 of them wrote that each proposal in de Grey's programme was, "at our present stage of ignorance, exceptionally optimistic", and that reversing aging within our lifetime "is so far from plausible that it commands no respect at all within the informed scientific community."²⁵ A long-running wager marks a narrower disagreement. In 2001 Steven Austad bet S. Jay Olshansky that someone would live to 150 by 2150, cognizant of their surroundings throughout, while Olshansky bet that 130 years is the top end of the human lifespan; three scientists are to settle it on 1 January 2150.²⁶

§Evidence from interventions

No intervention has extended maximum human lifespan, and none has been tested in a way that could show it. The animal record is real but modest, and it differs sharply by species.

• Mice. In the Interventions Testing Program, Rapamycin fed from 600 days of age increased the age at 90% mortality by 14% in female and 9% in male genetically heterogeneous mice.²⁷ Caloric restriction also extends maximum lifespan in rodents.
• Dogs. In a paired study of 48 Labrador retrievers, dogs fed 25% less than their pair-mates from eight weeks of age had a significantly longer median lifespan.²⁸ As of November 2026 no drug trial in dogs has reported a lifespan result. The Dog Aging Project's rapamycin trial had enrolled 170 dogs by December 2024 with a target of 580,²⁹ and Loyal's STAY study of its drug LOY-002 is fully enrolled at 1,300 dogs and remains blinded.³⁰
• Primates. Two long-running studies of calorie restriction in rhesus monkeys disagreed: the Wisconsin study reported fewer age-related deaths,³¹ while the National Institute on Aging study found no improvement in survival.³² A joint 2017 analysis attributed the difference partly to study design and concluded that the health benefits are conserved in monkeys.³³ For rapamycin in common marmosets, the researcher Adam Salmon told public radio in 2024 that his team had concluded the drug extended lifespan; that report gave no effect size and was not a peer-reviewed paper.³⁴
• Humans. Calorie-restriction trials address biomarkers and cardiometabolic risk, not the tail. Senolytics, rapamycin and other geroprotector candidates have not been tested on a timescale that could show such an effect, and no validated surrogate exists that would let them be tested faster.

The mammalian effects reported so far are increments: percentages of lifespan in mice, a longer median in one dog study. Arguments about whether that will change concern future medicine; they are not evidence that it has. Cryonics is the fallback bet for those who expect no such change within their own lifetime.

§Outlook

The question that would settle the debate is empirical and slow: as the number of people reaching 105 keeps growing, does the maximum reported age at death grow with it? Extreme-value theory makes a testable prediction. A thin exponential tail produces a slowly rising record, and a truncated one produces a flat record. The datasets needed to tell them apart accumulate at a rate set by human generations. Better birth registration in the cohorts now entering old age will do more to resolve the question than any new statistical method, since the current dispute concerns data quality at least as much as biology. A second, faster route would be a molecular measure that tracked the tail directly. If an epigenetic or proteomic measure could distinguish a 112-year-old who will reach 120 from one who will not, the ceiling question would become answerable without waiting for the deaths.

§See also

• Longevity escape velocity
• Negligible senescence
• Blue Zones
• Healthspan
• Compression of morbidity
• Hallmarks of aging
• Geroscience hypothesis
• Interventions Testing Program

§References